The analysis is based on population modelling using data from Dutch populations. The paper concludes that treatment is "cost-effective for men with a 10-year cardiovascular disease risk of >10% and for women with a risk of >15%".
A similar analysis undertaken several years ago by Bandolier examined the risks and benefits of treatment. It concluded that treatment was safe and worthwhile at a coronary risk of >15% in 10 years (approximately 20% CVD risk). It was also noted that treatment safe but of limited value in terms of risks and benefits at 10% CHD risk over 10 years (approximately 15% CVD risk).
Action: Clinicians should ensure that any patient whose cardiovascular risk is estimated at greater than 20% in 10 years should be offered treatment with low-dose aspirin and a cost-effective statin (usually simvastatin 40mg).